Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.11.2022 | Case report

Certolizumab-pegol

Severe acquired haemophilia: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Yella R, et al. Severe acquired hemophilia as a complication of anti-TNF therapy responding to high dose prednisone, rituximab and the bispecific antibody emicizumab. Swiss Medical Weekly 152 (Suppl. 261): 18S, Aug 2022. Available from: URL: https://smw.ch/article/doi/smw.2022.w30233 [abstract] Yella R, et al. Severe acquired hemophilia as a complication of anti-TNF therapy responding to high dose prednisone, rituximab and the bispecific antibody emicizumab. Swiss Medical Weekly 152 (Suppl. 261): 18S, Aug 2022. Available from: URL: https://​smw.​ch/​article/​doi/​smw.​2022.​w30233 [abstract]
Metadaten
Titel
Certolizumab-pegol
Severe acquired haemophilia: case report
Publikationsdatum
01.11.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-28509-1

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Multiple drugs

Case report

Teicoplanin

Case report

Phytomenadione

Case report

Multiple drugs

Case report

Multiple drugs

Case report

Eplerenone